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Strengths and limitations of this study
 ► The study has a long-term follow-up and will pro-
vide knowledge on the effects of different levels of 
carbohydrate counting.
 ► The study applies well-documented measures of 
glycaemic control as effect parameters.
 ► The results obtained have applicability beyond 
Denmark and has the potential to be included in the 
recommendations in future guidelines.
 ► A limitation is the lack of a dietary ‘untreated’ con-
trol group, however; it would be unethical not to 
offer standard dietary care for patients with type 1 
diabetes.
 ► The difference in the number of hours and type of 
dietary education and support between the groups 
may also influence the participants’ learning.
AbStrACt
Introduction Clinical guidelines recommend that 
patients with type 1 diabetes (T1D) learn carbohydrate 
counting or similar methods to improve glycaemic control. 
Although systematic educating in carbohydrate counting 
is still not offered as standard-of-care for all patients on 
multiple daily injections (MDI) insulin therapy in outpatient 
diabetes clinics in Denmark. This may be due to the lack 
of evidence as to which educational methods are the most 
effective for training patients in carbohydrate counting. 
The objective of this study is to compare the effect of 
two different educational programmes in carbohydrate 
counting with the usual dietary care on glycaemic control 
in patients with T1D.
Methods and analysis The study is designed as a 
randomised controlled trial with a parallel-group design. 
The total study duration is 12 months with data collection 
at baseline, 6 and 12 months. We plan to include 231 
Danish adult patients with T1D. Participants will be 
randomised to one of three dietician-led interventions: 
(1) a programme in basic carbohydrate counting, (2) a 
programme in advanced carbohydrate counting including 
an automated bolus calculator or (3) usual dietary care. The 
primary outcome is changes in glycated haemoglobin A1c 
or mean amplitude of glycaemic excursions from baseline 
to end of the intervention period (week 24) between and 
within each of the three study groups. Other outcome 
measures include changes in other parameters of plasma 
glucose variability (eg, time in range), body weight and 
composition, lipid profile, blood pressure, mathematical 
literacy skills, carbohydrate estimation accuracy, dietary 
intake, diet-related quality of life, perceived competencies 
in dietary management of diabetes and perceptions of an 
autonomy supportive dietician-led climate, physical activity 
and urinary biomarkers.
Ethics and dissemination The protocol has been 
approved by the Ethics Committee of the Capital 
Region, Copenhagen, Denmark. Study findings will be 
disseminated widely through peer-reviewed publications 
and conference presentations.
trial registration number  ClinicalTrials. gov Registry 
(NCT03623113).
IntroduCtIon
Carbohydrate is the nutrient in our diet with 
by far the highest impact on plasma glucose 
levels. The total amount of carbohydrates 
consumed in a meal is the major predictor 
of the postprandial glucose response. Thus, 
monitoring dietary intake of carbohydrates 
is important to control postprandial glucose 
fluctuations, which may lead to clinical bene-
fits such as a reduction in glucose variability, 
an improvement of glycated haemoglobin 
A1c (HbA1c) and a reduction in diabetes-re-
lated complications.
Clinical guidelines in medical nutrition 
therapy recommend that patients with type 1 
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or similar experience-based methods to improve 
glycaemic control.1–4 Two levels of carbohydrate counting 
have been defined internationally with different learning 
objectives and increasing complexity; a basic and an 
advanced level.5 6 Basic carbohydrate counting (BCC) 
includes understanding of the relationship between food, 
physical activity and plasma glucose levels with special 
attention on consistency in the timing, type, amount and 
distribution of carbohydrate-containing foods consumed. 
Advanced carbohydrate counting (ACC) is targeting the 
patient who ideally masters BCC, is on intensive insulin 
therapy and prepared to learn how to adjust insulin 
according to carbohydrate intake. In the clinical guide-
lines and studies, the term ‘carbohydrate counting’ is 
often used synonymously with ACC, while the sole effect of 
BCC on glycaemic control is largely unknown. Systematic 
reviews and meta-analyses of randomised controlled trials 
(RCTs) have shown that ACC can reduce HbA1c by up 
to 7 mmol/mol in adults with poorly controlled T1D.7–9 
Despite this, systematic educating and training is still not 
offered routinely for patients on multiple daily injections 
(MDI) therapy in outpatient clinics in Denmark. This 
may be due to the lack of evidence as to which educa-
tional methods are the most effective for training patients 
in carbohydrate counting in terms of supporting patients 
in implementation and ongoing adherence to the use 
of carbohydrate counting as a tool for meal planning in 
their daily life.
Ideally, patients with T1D treated on MDI therapy need 
to be able to manage the following steps of calculation 
when using carbohydrate counting: (1) correct calculation 
of the total carbohydrate content in each meal according 
to portion sizes of each carbohydrate-containing food 
item (equal to BCC) and (2) correct calculation of 
insulin dose according to the amount of carbohydrates 
to be consumed using a carbohydrate-to-insulin ratio, 
an insulin sensitivity factor, and the current and target 
plasma glucose (equal to ACC). In other words, patients 
with diabetes need good mathematical literacy skills, 
including numeracy skills, to be able to practice the 
above-mentioned steps several times each day. Recent 
studies suggest that lower literacy and numeracy skills are 
associated with poorer portion size estimation, under-
standing of food labels, diabetes-related self-manage-
ment abilities, diabetes control and increased body mass 
index.10–16 Other studies have found that patients with 
diabetes frequently assess their intake of carbohydrates 
inaccurately and this has been associated with a poorer 
HbA1c.17–19 Particularly mixed meals, high-calorie foods 
and larger portion sizes resulted in inaccurate carbohy-
drate estimation. One study also found that underesti-
mation of carbohydrate-rich meals was associated with 
higher daily plasma glucose variability in adults with 
T1D.20 Thus, assessment of numeracy skills is highly rele-
vant to ensure that a nutritional education programme 
address patients with low literacy and numeracy. This may 
be done by numeracy-focused educational exercises and 
materials or hands-on learning.
In recent years, technological innovations including 
applications (apps) for smartphones have been intro-
duced to reduce the complexity of carbohydrate counting 
and possibly compensate for poor numeracy skills. So far, 
no technological devices can replace the patients’ self-es-
timations of the carbohydrate content in most meals, for 
example, in mixed meals (addressing step 1). RCTs have 
demonstrated that ACC supported by the use of auto-
mated bolus calculator (ABC) software to assist insulin 
dose decision-making (addressing step 2) compared 
with unassisted ACC significantly improves HbA1c and 
treatment satisfaction in patients with T1D treated with 
MDI.21–23 However, a recent exploratory study found that 
lower numeracy skills were associated with smaller reduc-
tions in HbA1c after a 12-month education programme 
in ACC with no benefit from the use of an ABC compared 
with manual calculations.24 These findings support the 
need for more intensified dietary education in BCC 
before learning ACC. Additionally, the concept of ACC 
may not be useful in all patients with T1D on MDI therapy 
because of potential patient barriers, lack of motivation 
to learn the method and low levels of education, literacy 
or numeracy skills. Other barriers include lack of appro-
priate learning environments to promote behavioural 
change and availability of trained dietitians to facilitate 
the learning process.25 In a study of patients with diabetes, 
perceived competence was predicted by the degree to 
which the patients experienced the healthcare climate 
to be autonomy supportive, and perceived competence 
at carrying out the treatment in turn predicted HbA1c.26 
Group-based approaches with practised-focused dietary 
education compared with individual dietary counselling 
have been practiced in some settings but are underinves-
tigated.27 In line with this, we are currently carrying out 
an RCT based on this protocol.
AIM
The aims are to examine the effectiveness of two different 
group-based dietitian-led practise-focused educational 
approaches for dietary self-management compared with 
the standard nutrition education on glycaemic control in 
patients with T1D. The BCC concept aims at improving 
carbohydrate counting accuracy and day-to-day consis-
tency of carbohydrate intake (the BCC intervention) and 
the concept of ACC aim at improving prandial insulin 
dose accuracy using an ABC (the ABC-ACC intervention).
MEthodS And AnAlySIS
Study design
The study is as a randomised controlled intervention trial 
with a parallel-group design (see figure 1). The study 
duration is 48 months for each participant and includes 
up to seven visits at the study site (see figure 2). All partici-
pants will be instructed to maintain their habitual lifestyle 
in all other aspects than their diet, for example, keeping 
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Figure 1 Study design. ABC-ACC, advanced carbohydrate counting with an automated bolus calculator; BCC, basic 
carbohydratecounting.
Figure 2 Schematic diagram of the intervention. ABC-ACC,advanced carbohydrate counting with an automated bolus 
calculator; BCC, basic carbohydrate counting; BP, blood pressure; BW, body weight; CGM, continuous glucose monitoring; 
DXA, dual-energy-X-ray absorptiometry; V, visit; WHC,waist-hip circumference.
All participants will be instructed to follow their regular 
diabetes care in the hospital, which usually includes 
4 yearly visits with a diabetologist (endocrinologist) and 
1 yearly consultation with a diabetes nurse. Participants 
will be instructed not to receive any further dietary educa-
tion during the study period. Close relatives can partici-
pate in the dietary education in all three study groups if 
the participant needs support to manage dietary changes.
The study flow is presented in figure 3. The study 
follows the guidelines of Standard Protocol Items for 
Randomised Trials.
Setting
The study will be carried out in the outpatient diabetes 
clinic at Steno Diabetes Center Copenhagen (SDCC) in 
Gentofte, Denmark.
recruitment and consent
As a temporary supplementary treatment initiative, SDCC 
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Figure 3 Study flow diagram. The planned flow of 
participants through the stages of the study. ABC-ACC, 
advanced carbohydrate counting with an automated bolus 
calculator; BCC, basic carbohydrate counting.
T1D treated in the capital region of Denmark. Partic-
ipants for the current study will be recruited among 
patients signing up for these courses or patients directly 
referred to one of the courses or the study by a health-
care professional (diabetologist, diabetes nurse or dieti-
tian) from SDCC or from a Steno Partner hospital in 
the capital region. A course administrator at SDCC will 
contact all interested or referred patients by telephone 
and provide information about the study. In addition, 
potential study participants will be recruited through 
information on  sdcc. dk and other electronic media or 
patient-related networks. If the patient is interested in the 
study, the patient will receive the written patient informa-
tion by mail or email. If interested in study participation, 
the study investigator/study personnel will schedule a 
personal meeting for oral patient information, offering 
the possibility of bringing a confidant. The patient will be 
given time to discuss any questions and will be informed 
that he/she has at least 24 hours to decide on participa-
tion in the study. If the patient decides to participate in 
the study, the patient and the study investigator/study 
personnel will sign the written informed consent, and the 
investigator/study personnel will perform a screening. If 
all inclusion criteria are fulfilled and none of the exclu-
sion criteria are met, the patient will be included in the 
study and randomised to one of three groups. Patients 
who decline to participate or do not meet the inclusion 
criteria will continue their usual care in an outpatient 
diabetes clinic and will be offered to participate on a BCC 
or ACC course if they still wish to do so. Participants will 
be informed that participation is voluntary, and that they 
may withdraw their consent at any time.
Inclusion criteria
Patients with T1D between 18 and 75 years of age with 
a diabetes duration above 12 months and with an initial 
HbA1c of 53–97 mmol/mol on MDI therapy with a basal-
bolus insulin regime are eligible for the study.
Exclusion criteria
Patients are excluded if they have other types of diabetes 
than T1D, are practicing carbohydrate counting as judged 
by the investigator, have a low daily intake of carbohydrates 
(defined as <25 E% or 100 g/day), have participated in 
a BCC group programme within the last 2 years, use an 
insulin pump or plan to have an insulin pump within 
the study period, use split-mixed insulin therapy, use 
an ABC, have gastroparesis, have uncontrolled medical 
issues affecting the dietary intake as judged by the inves-
tigator or a medical expert. Women who are pregnant or 
breastfeeding or have plans of pregnancy within the study 
period are also excluded. Furthermore, patients who are 
either participating in other clinical studies or are unable 
to understand the informed consent and the study proce-
dures will be excluded.
randomisation
Participants eligible for inclusion in the study will be 
randomly allocated in a 1:1:1 ratio to one of the three 
groups (BCC, ABC-ACC or control) using a comput-
er-generated randomisation in the software programme 
REDCap. The randomisation is done by stratifying partic-
ipants based on sex and HbA1c at baseline. The rando-
misation is done in blocks in order to ensure an equal 
number of participants in each group.
Intervention groups
The BCC programme consists of two sessions of 3 hours 
and a follow-up group session of 2 hours. The BCC 
programme uses trained dietitians following a planned 
curriculum which include experience-based learning 
with problem-solving exercises, hands-on activities, short 
theoretical presentations, discussions of motivational 
aspects and coping strategies. The BCC programme inte-
grates peer modelling, skills development, goal setting, 
observational learning and social support into the 
programme content and activities. The training includes 
identifying carbohydrates in food, reading carbohydrate 
tables, calculating the carbohydrate content from food 
labels, tables and apps and use of a personalised carbo-
hydrate plan with guiding suggestions for daily intake 
of carbohydrates at meals based on 4 days of personal 
dietary recording performed before the programme 
including plasma glucose measurements and prandial 
insulin dosages taken. An app (Diabetes og Kulhydrattælling. 
The Danish Diabetes Association, Pragma soft A/S, avail-
able in Google Play and AppStore) will be introduced to 
support estimation and calculation of carbohydrates and 
assist in simple insulin dose determination if participants 
choose to consume more carbohydrates at a meal than 
suggested in their personal carbohydrate plan.
The ABC-ACC programme consists of a 4-hour group 
session and two individual follow-up sessions (two 45 min 
sessions). The programme uses trained dietitians with 
supervision by a medical doctor and follows a planned 
curriculum. The ABC-ACC intervention is a group-based 
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Table 1 Schematic overview of outcomes measured
Week no from start of intervention –4 to –1 12 24 48
HbA1c X X X X
Plasma lipids X   X X
Body weight X   X X
Height X       
Waist and hip circumference X   X X
Blood pressure X   X X
Blood samples, fasting X   X X
Urine samples for 4 days* X   X   
Glucose variability (CGM) including 
PG diary for 6 days*
X   X   
Body composition (DXA) X   X   
Prescribed lipid-lowering and 
glucose-lowering medication
X   X X
F: dietary registration for 4 days* X   X   
Q: diet-related quality of life X   X X
Q: perceived competencies in 
diabetes
X   X X
Q: healthcare climate X   X   
Q: carbohydrate estimation 
accuracy
X   X X
Q: mathematical literacy X   X X
Q: demographic data X       
Q: physical activity X   X X
*Measured in the days following the study visits.
CGM, continuous glucose monitoring; DXA, dual-energy-X-ray 
absorptiometry; F, forms; HbA1c, haemoglobin A1c; PG, plasma 
glucose; Q, questionnaire.
BolusCal concept.28 The programme includes fast training 
in BCC, ACC and bolus calculation using an ABC (mySugr 
Pro. Roche, available in Google Play and AppStore) taking 
insulin onboard, insulin sensitivity factor and differenti-
ated carbohydrate-to-insulin ratios during the day into 
account. The carbohydrate-to-insulin ratios are based 
on 7 days of personal dietary recording including plasma 
glucose measurements and prandial insulin dosages 
taken. The ABC-ACC programme contains theoretical 
and practical training. The teaching is based on theory 
and examples from everyday life with T1D and the educa-
tors help the participants with their specific diabetes-re-
lated problems and try to find appropriate practical 
solutions together with the participant.
Control group
Participants randomised to the control group receive 
current standard outpatient nutrition education in T1D. 
This includes individual guidance by a trained dieti-
tian, with one initial 60 min dietary counselling session 
and two individual 30 min follow-up session. The indi-
vidual guidance is based on the overall treatment goal 
and the defined personal dietary goals for behavioural 
change according to patient preferences. Dietary guid-
ance includes topics such as carbohydrate sources (eg, 
practicing glycaemic index and dietary fibre intake) and 
amounts of carbohydrates or more general dietary recom-
mendations according to patient needs.
delivery of dietary education
The educational programme in both the standard treat-
ment group and the intervention groups will be delivered 
by the same study dietitians. The dietitians have been 
trained by the PI (Bettina Ewers) in what to deliver in 
each study-arm according to the study protocol and in 
case of doubt, they will discuss each case with the PI to 
make sure that they provide the correct guidance to all 
participants. Data on which of the dietitians each partici-
pant has been exposed to during the trial is registered for 
later data analysis. Additionally, all study dietitians have 
an interest in providing the best possible dietary guidance 
irrespective of it being the standard treatment or the two 
intervention concepts being tested.
data collection
All study data will be collected at the three visits with clin-
ical examinations (baseline, after 6 and 12 months). Data 
will be obtained from a self-reported patient question-
naire, electronic medical records and the physical exam-
inations conducted by the study investigator or study 
personnel. All questionnaire data will be collected elec-
tronically using the software system REDCap according to 
local standards for research projects in the capital region 
of Denmark. In addition, all sources will be registered 
in this database. Data generated and stored for specific 
equipment (eg, dual-energy-X-ray absorptiometry (DXA) 
data stored in the DXA scanner software database), elec-
tronic medical data (blood and urine measurements, 
glucose-lowering and lipid-lowering medicine), data from 
iPro2 CGM using software from Medtronic (Northridge, 
California, USA) to download continuousglucose moni-
toring (CGM) measurements, dietary data on total energy 
and nutrients based on calculations from the software 
system Vitakost will be added to the database in REDCap 
on an ongoing basis and at the end of study.
The primary outcome is the difference in mean HbA1c 
or mean amplitude of glycaemic excursions (MAGE) 
from baseline to end of the intervention (week 24) 
between and within each of the three study groups (BCC, 
ABC-ACC and control).
A schematic overview of outcomes measurements is 
presented in table 1.
Secondary outcomes are listed below
Clinical parameters
Body weight, body composition (measured by DXA), 
waist and hip circumference, blood pressure, type and 
dose of prescribed glucose-lowering and lipid-lowering 
medication, other parameters of plasma glucose vari-
ability including time in range (3.9–10.0 mmol/L), 
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time spent in hyperglycaemia (eg, >10.0 mmol/L) 
and SD of mean plasma glucose assessed from CGM 
measurements.
Blood and urine samples
HbA1c (after 12 and 48 weeks), plasma lipids (low-den-
sity lipoprotein cholesterol, high-density lipoprotein 
cholesterol, very low-density lipoprotein cholesterol, total 
cholesterol, free fatty acids and triglycerides), alanine 
aminotransferase, urine albumin/creatinine ratio and 
urinary biomarkers based on three daily midstream urine 
spots collected for 4 days.
Patient-reported outcomes
Diet-related quality of life, perceived competencies in 
diabetes, healthcare climate, carbohydrate estimation 
accuracy, mathematical literacy skills, physical activity and 
demographic questions. The six questionnaires used are 
as follows.
Diabetes diet-related quality of life questionnaire
The diabetes diet-related quality of life questionnaire 
(DDRQOL) is a 31-item scale which has been validated 
in patients with diabetes.29 The scale is designed to deter-
mine the quantitative and qualitative satisfaction with diet 
and the degree of restriction of daily life and social life 
functions due to the dietary changes. A forward transla-
tion and cultural adaption of the DDRQOL was done by a 
Japanese-Danish interpreter with a background as a clin-
ical dietitian and an expert panel of six clinical dietitians 
working with diabetes. This was followed by a pilot testing 
by 10 patients with diabetes.
Perceived Competencies in Diabetes Scale
The Perceived Competencies in Diabetes Scale includes 
four items that reflect participants’ feelings of compe-
tence about engaging in a healthier behaviour and 
participating in a nutritional education programme. 
Forward and backward linguistic translation from English 
to Danish has been done according to standard proce-
dures in 2001 under the guidance of Professor Vibeke 
Zoffmann.
Healthcare Climate Questionnaire
The Healthcare Climate Questionnaire chosen in this 
study is a 5-item short form of the originally validated 
15-item measure that assesses patients’ perceptions of the 
degree to which dieticians are autonomy supportive vs 
controlling in providing dietary treatment.
Carbohydrate photographic questionnaire
The carbohydrate photographic questionnaire (CPQ) is 
an electronic questionnaire assessing diabetes patients’ 
abilities to estimate portion sizes of 11 commonly eaten 
high-carbohydrate foods correctly. The CPQ has been 
developed and validated against real food in 87 patients 
with T1D. A manuscript of these study results has been 
submitted (Ewers et al, unpublished).
Mathematical literacy questionnaire
A 10-item test with modified questions from the nutri-
tion domain of the Diabetes Numeracy Test (DNT)30 was 
designed and feasibility tested to investigate mathemat-
ical literacy including numeracy skills (addition, subtrac-
tion, division and multiplication) which are essential for 
understanding numbers and applying mathematical skills 
in daily life, for example, for calculating carbohydrates.
International Physical Activity Questionnaire Short Form
The Danish version of the InternationalPhysical Activity 
Questionnaire Short Form31 will be used to assess changes 
in level of physical activity during the study period.
Demographic data
Self-reported demographic questions include level of 
education, occupation, marital status, household compo-
sition and yearly income.
Dietary data
Four days of weighed dietary food records collected at 
baseline and 6 months after baseline. Dietary records will 
be calculated using the software system Vitakost where 
nutrient and energy calculations are based on the Danish 
national food database. The dietary food records are used 
to estimate total energy intake (kJ/day), intake of carbo-
hydrates, protein and fat (g/day and g/meal), added 
sugar (g/day) and total dietary fibre intake (g/day). The 
dietitian performing the analysis of the food records 
only have access to the study ID number and participant 
initials.
Baseline data (from the electronic medical record)
Type of diabetes, diabetes duration, use of an open 
CGM, use of Freestyle Libre, gender, age, smoking status, 
medical conditions, total number of visits at a diabetolo-
gist and diabetes nurse and dietician during and one year 
prior to the study period.
data analysis plan
The trial is ongoing. The patient recruitment started 
in October 2018 and is expected to be completed by 
October 2021.
Sample size calculation
A power calculation was conducted based on the primary 
outcome measures HbA1c and MAGE. Allowing for an 
estimated drop-out rate of 20% and subgroup analyses 
the sample size was planned to include a total of 231 
patients in the study (77 in each arm). This was based on 
a sample size calculation which suggested that including 
64 participants in each of the study groups would give 
80% power to detect a clinically meaningful difference 
in change in HbA1c of 3.5 mmol/mol between the BCC 
group versus the control group or the ABC-ACC group 
versus the control group with a 5% significance level using 
a two-sided test and an estimated SD of 7 mmol/mol. This 
SD has previously been used for sample size calculations 
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evaluation of previous conducted BCC courses at SDCC 
on mean changes and SD of HbA1c after 6 months among 
completers with T1D (n=185). MAGE has only been used 
as an outcome measure of glucose variability in a few 
randomised controlled dietary intervention studies of 
patients with diabetes32 33 showing differences in changes 
in MAGE up to 4.8 mmol/L (SD: 1.0) after a 12-week 
carbohydrate counting intervention,32 but is regularly 
used in other clinical studies evaluating glucose variability 
. By including 77 participants in each study group, we will 
have a power of 80% (alpha level of 0.05) in a two-sided 
test to detect a clinically meaningful difference in the 
change in MAGE during the intervention period (week 
24) of ≥0.35 mmol/L (SD 0.7 mmol/L) between the study 
groups.
Statistical methods
Analysis and reporting of the study results will follow the 
Consolidated Standards of Reporting Trials guidelines for 
reporting parallel group randomised trials.34 Results will 
be presented as means (SD) for normally distributed vari-
ables and as medians (IQR) for non-normally distributed 
variables.
One-way analysis of variance (ANOVA) will be used to 
compare baseline data between the three study groups 
for normal data and Kruskal-Wallis H test for non-normal 
data. Paired samples t-test will be used for within group 
comparison for normal data and Wilcoxon signed rank 
test for non-normal data. Mixed-effect models will be used 
to test differences in outcomes from baseline to follow-up 
to take repeated measurements into account. If model 
assumptions cannot be met even after logarithmic trans-
formation, non-parametric tests will be used. Examina-
tions of the relevant diagnostic plots, including QQ-plots, 
will be used to evaluate normality of the residuals.
The baseline demographics as well as clinical and 
diabetes-related characteristics of the intervention and 
the control groups will be presented and compared. The 
average changes between baseline and week 24 and 48 
in primary and secondary outcomes will be calculated 
for each of the three groups. Intention-to-treat (ITT) 
analysis will be performed as the primary analysis on all 
primary and secondary outcomes after the last partic-
ipant has ended participation. Missing values will be 
handled with a last observation carried forward approach 
for ITT analysis with the use of the multiple imputation 
approach in a sensitivity analysis. Per protocol analysis 
will only be performed in case of sensitivity testing. Meta-
bolic patterns will be tested with multivariate statistics. 
Adjustment for relevant confounders will be performed 
including adjustment for the stratified variables. Hetero-
geneity in responsiveness to the interventions will be 
tested by dividing each intervention group into smaller 
groups based on data distribution (medians) or clinically 
meaningful cut-points. Two-sided tests will be used. P 
values of <0.05 are considered significant. The statistical 
programmes SPSS version 22.0 and SAS Enterprise Guide 
7.1 or newer versions will be used for data analysis.
Patient and public involvement
Patients were involved in developing the educational 
content of the BCC programme. Patients were not 
involved in setting the research questions or the outcome 
measures, nor were they involved in developing the study 
design. Information may be disseminated to the public 
via any media coverage of study findings.
EthICS And dISSEMInAtIon
The study will be conducted in accordance with the 
ethical principles in the Declaration of Helsinki and to 
the regulations for Good Clinical Practice to the extent 
that this is relevant for non-medical studies. The study has 
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